Bronsted-basic small molecules activate GTP hydrolysis in Ras Q61 mutants

The RAS oncogenes (KRAS, HRAS, NRAS) are among the most frequently mutated genes in human cancer, affecting over three million patients annually. Therapeutic development has largely focused on inhibitors for KRAS codon 12 mutations (G12C/D/V/S/R) which are key drivers in lung, colorectal, and pancreatic cancers. In contrast, mutant-selective inhibitors for Q61 variants remain elusive. A common mechanistic feature of G12 and Q61 mutants is the impaired hydrolysis of GTP, which traps Ras in its active, signaling-competent state. We envisioned that an alternative therapeutic strategy - reactivation of GTP hydrolysis - could address this shared oncogenic mechanism. Here we report small molecules that accelerate GTP hydrolysis in K-Ras Q61 mutants. These compounds compensate for the loss of the catalytic residue Gln61 by introducing a general base into the active site, selectively enhancing hydrolysis of K-Ras Q61X (X = H, L, K, R) mutants by up to 20-fold while sparing the wild-type protein. In mutant cancer cell lines, these compounds reduce GTP-bound Ras levels and suppress downstream signaling. We show that the chemical design principles are generalizable to other Ras isoforms. This work establishes a mechanistic foundation for small-molecule "GTPase activators" and offers a new paradigm for targeting Ras-driven cancers.